Related Experiment Video
Updated: Mar 14, 2026
Simplified Whole Body Plethysmography to Characterize Lung Function During Respiratory Melioidosis
Published on: February 24, 2023
The Treatment of Melioidosis
Timothy J J Inglis1,2,3
1Division of Microbiology & Infectious Diseases, PathWest Laboratory Medicine WA, QEII Medical Centre, Nedlands, WA 6009, Australia. tim.inglis@health.wa.gov.au.
Abstract:
Melioidosis is a complex bacterial infection, treatment of which combines the urgency of treating rapidly fatal Gram negative septicaemia with the need for eradication of long-term persistent disease in pulmonary, soft tissue, skeletal and other organ systems. Incremental improvements in treatment have been made as a result of multicentre collaboration across the main endemic region of Southeast Asia and northern Australia. There is an emerging consensus on the three main patterns of antimicrobial chemotherapy; initial (Phase 1) treatment, subsequent eradication (Phase 2) therapy and most recently post-exposure (Phase 0) prophylaxis. The combination of agents used, duration of therapy and need for adjunct modalities depends on the type, severity and antimicrobial susceptibility of infection. New antibiotic and adjunct therapies are at an investigational stage but on currently available data are unlikely to make a significant impact on this potentially fatal infection.
Insights
Melioidosis treatment requires addressing both acute Gram-negative septicaemia and chronic infections. Current strategies involve phased antimicrobial chemotherapy, with ongoing research for new therapies.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Antimicrobial Chemotherapy
Background:
- Melioidosis is a complex bacterial infection with potential for rapid fatality and long-term persistence.
- Effective treatment necessitates managing acute Gram-negative septicaemia and eradicating chronic disease in various organ systems.
- Multicentre collaboration in endemic regions has led to incremental treatment improvements.
Approach:
- Emerging consensus on a three-phase antimicrobial chemotherapy approach: initial (Phase 1), eradication (Phase 2), and prophylaxis (Phase 0).
- Treatment regimens are tailored based on infection type, severity, and antimicrobial susceptibility.
- Investigational new antibiotics and adjunct therapies are under evaluation.
Key Points:
- Phase 1: Urgent treatment of acute Gram-negative septicaemia.
- Phase 2: Eradication therapy for persistent pulmonary, soft tissue, and skeletal infections.
- Phase 0: Post-exposure prophylaxis strategies are under development.
Conclusions:
- Current treatment protocols are evolving with a phased approach to antimicrobial chemotherapy.
- Adjunct therapies and new antibiotics are investigational and their impact on this fatal infection is yet to be determined.
More Related Videos
06:19Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
Published on: October 11, 2024
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:26Pharmaceutical Poisoning: Treatment Strategies
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy